Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 61, Issue 3, Pages 248-255Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2008.12.012
Keywords
CpG; Adjuvant; Vaccine; Immunogenicity; Antibody; IFNg; Protection
Categories
Ask authors/readers for more resources
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, accelerating and boosting antigen-specific immune responses. CpG motifs promote the induction of Th1 and pro-inflammatory cytokines and support the maturation/activation of professional antigen presenting cells (particularly plasmacytoid dendritic cells). These effects are optimized by maintaining close physical contact between the CpG ODN and the immunogen. Co-administering CpG ODN with a variety of vaccines has improved the resultant humoral and/or cellular immune responses, culminating in enhanced protective immunity in rodent and primate challenge models. Ongoing clinical studies indicate that CpG ODN are safe and well-tolerated when administered as adjuvants to humans, and that they can support increased vaccine-specific immune responses. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available